BHC · NYSE
Bausch Health Companies Inc.
$7.86 +1.55 (+24.56%)
Company overview
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on vision care, surgical, and consumer ophthalmic pharmaceuticals. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, as well as Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Exchange
- NYSE
- Market cap
- $2.9B
- Employees
- 20,700
- Headquarters
- Laval, QC
- Website
- bauschhealth.com
- CEO
- Thomas J. Appio
- Listed
- March 29, 1994
- P/E
- -2.45
- Dividend yield
- 4.99%
Company financials
- Revenue
- $10.6B
- Gross profit
- $6.5B
- Operating income
- $2.4B
- EBITDA
- $3.6B
- Net income
- -$1.2B
- EPS
- -$3.21
- Total assets
- $24.5B
- Total debt
- $20.8B
- Gross margin
- 61.67%
- Net margin
- -11.27%
- Earnings yield
- -40.84%
Showing FY 2025
BHC
1D
NYSE
O6.37H6.37L6.23C6.31-0.04 (-0.63%)Vol1.56M